Serum IL-6: A candidate biomarker for intracranial pressure elevation following isolated traumatic brain injury

Journal of Neuroinflammation

Volumn 7, Issue , 2010, Pages

  Hergenroeder, Georgene W ^a   Moore, Anthony N ^a   McCoy Jr, J Philip ^b   Samsel, Leigh ^b   Ward III, Norman H ^a   Clifton, Guy L ^a   Dash, Pramod K ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MONOCLONAL ANTIBODY; CYTOKINE;

ADOLESCENT; ADULT; AGED; APACHE; ARTICLE; ASSAULT; BLOOD ANALYSIS; BONE INJURY; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; CONTUSION; DIFFERENTIAL DIAGNOSIS; DIFFUSE AXONAL INJURY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDURAL HEMATOMA; FALLING; FEMALE; GLASGOW COMA SCALE; HUMAN; INCIDENCE; INTRACRANIAL HYPERTENSION; INTRACRANIAL PRESSURE MONITORING; MALE; MULTIPLE TRAUMA; PREDICTION; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SKULL FRACTURE; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; TRAFFIC ACCIDENT; TRAUMATIC BRAIN INJURY; ANALYTICAL EQUIPMENT; BLOOD; BRAIN INJURY; COMPUTER ASSISTED TOMOGRAPHY; FRACTURE; INJURY SCALE; MIDDLE AGED; NEUROPHYSIOLOGICAL RECRUITMENT; PHYSIOLOGY; PREDICTION AND FORECASTING; REPRODUCIBILITY;

ADOLESCENT; ADULT; AGED; APACHE; BIOLOGICAL MARKERS; BRAIN INJURIES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FRACTURES, BONE; GLASGOW COMA SCALE; HUMANS; INJURY SEVERITY SCORE; INTERLEUKIN-6; INTRACRANIAL HYPERTENSION; MALE; MIDDLE AGED; MULTIPLE TRAUMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REAGENT KITS, DIAGNOSTIC; RECRUITMENT, NEUROPHYSIOLOGICAL; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 77949479811     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-7-19     Document Type: Article

References (50)

1. Stocchetti N, Colombo A, Ortolano F, Videtta W, Marchesi R, Longhi L, et al. Time course of intracranial hypertension after traumatic brain injury. J Neurotrauma 2007, 24:1339-1346. 10.1089/neu.2007.0300, 17711395.
2. Dearden NM. Mechanisms and prevention of secondary brain damage during intensive care. Clin Neuropathol 1998, 17:221-228.
3. Jantzen JP. Prevention and treatment of intracranial hypertension. Best Pract Res Clin Anaesthesiol 2007, 21:517-538. 10.1016/j.bpa.2007.09.001, 18286835.
4. Kadhim HJ, Duchateau J, Sebire G. Cytokines and brain injury: invited review. J Intensive Care Med 2008, 23:236-249. 10.1177/0885066608318458, 18504260.
5. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874. 10.1038/nature01323, 12490960.
6. Yamagami H, Kitagawa K, Nagai Y, Hougaku H, Sakaguchi M, Kuwabara K, et al. Higher levels of interleukin-6 are associated with lower echogenicity of carotid artery plaques. Stroke 2004, 35:677-681. 10.1161/01.STR.0000116876.96334.82, 14752126.
7. Patel RT, Deen KI, Youngs D, Warwick J, Keighley MR. Interleukin 6 is a prognostic indicator of outcome in severe intra-abdominal sepsis. Br J Surg 1994, 81:1306-1308. 10.1002/bjs.1800810914, 7953393.
8. Minambres E, Cemborain A, Sanchez-Velasco P, Gandarillas M, az-Reganon G, Sanchez-Gonzalez U, et al. Correlation between transcranial interleukin-6 gradient and outcome in patients with acute brain injury. Crit Care Med 2003, 31:933-938. 10.1097/01.CCM.0000055370.66389.59, 12627008.
9. Berger RP, Ta'asan S, Rand A, Lokshin A, Kochanek P. Multiplex assessment of serum biomarker concentrations in well-appearing children with inflicted traumatic brain injury. Pediatr Res 2008, 65:97-102.
10. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829. 10.1097/00003246-198510000-00009, 3928249.
11. Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet 1974, 2:81-84. 10.1016/S0140-6736(74)91639-0, 4136544.
12. Association for the Advancement of Automotive Medicine Abbreviated Injury Scale (AIS) 2005 - Update 2008 2008, Barrington, IL: AAAM Publications, Association for the Advancement of Automotive Medicine.
13. Bell MJ, Kochanek PM, Doughty LA, Carcillo JA, Adelson PD, Clark RS, et al. Comparison of the interleukin-6 and interleukin-10 response in children after severe traumatic brain injury or septic shock. Acta Neurochir Suppl (Wien) 1997, 70:96-97.
14. Kossmann T, Hans VH, Imhof HG, Stocker R, Grob P, Trentz O, et al. Intrathecal and serum interleukin-6 and the acute-phase response in patients with severe traumatic brain injuries. Shock 1995, 4:311-317. 10.1097/00024382-199511000-00001, 8595516.
15. Cui X, Kalsotra A, Robida AM, Matzilevich D, Moore AN, Boehme CL, et al. Expression of cytochromes P450 4F4 and 4F5 in infection and injury models of inflammation. Biochim Biophys Acta 2003, 1619:325-331.
16. Basu A, Krady JK, O'Malley M, Styren SD, DeKosky ST, Levison SW. The type 1 interleukin-1 receptor is essential for the efficient activation of microglia and the induction of multiple proinflammatory mediators in response to brain injury. J Neurosci 2002, 22:6071-6082.
17. John GR, Lee SC, Song X, Rivieccio M, Brosnan CF. IL-1-regulated responses in astrocytes: relevance to injury and recovery. Glia 2005, 49:161-176. 10.1002/glia.20109, 15472994.
18. Murphy PG, Grondin J, Altares M, Richardson PM. Induction of interleukin-6 in axotomized sensory neurons. J Neurosci 1995, 15:5130-5138.
19. Ringheim GE, Burgher KL, Heroux JA. Interleukin-6 mRNA expression by cortical neurons in culture: evidence for neuronal sources of interleukin-6 production in the brain. J Neuroimmunol 1995, 63:113-123. 10.1016/0165-5728(95)00134-4, 8550808.
20. Goodman JC, Van M, Gopinath SP, Robertson CS. Pro-inflammatory and pro-apoptotic elements of the neuroinflammatory response are activated in traumatic brain injury. Acta Neurochir Suppl 2008, 102:437-439. full_text, 19388362.
21. Csuka E, Morganti-Kossmann MC, Lenzlinger PM, Joller H, Trentz O, Kossmann T. IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: relationship to IL-6, TNF-alpha, TGF-beta1 and blood-brain barrier function. J Neuroimmunol 1999, 101:211-221. 10.1016/S0165-5728(99)00148-4, 10580806.
22. Kossmann T, Hans VH, Imhof HG, Stocker R, Grob P, Trentz O, et al. Intrathecal and serum interleukin-6 and the acute-phase response in patients with severe traumatic brain injuries. Shock 1995, 4:311-317. 10.1097/00024382-199511000-00001, 8595516.
23. Hans VH, Kossmann T, Joller H, Otto V, Morganti-Kossmann MC. Interleukin-6 and its soluble receptor in serum and cerebrospinal fluid after cerebral trauma. Neuroreport 1999, 10:409-412.
24. Singhal A, Baker AJ, Hare GM, Reinders FX, Schlichter LC, Moulton RJ. Association between cerebrospinal fluid interleukin-6 concentrations and outcome after severe human traumatic brain injury. J Neurotrauma 2002, 19:929-937. 10.1089/089771502320317087, 12225653.
25. Chiaretti A, Genovese O, Aloe L, Antonelli A, Piastra M, Polidori G, et al. Interleukin 1beta and interleukin 6 relationship with paediatric head trauma severity and outcome. Childs Nerv Syst 2005, 21:185-193. 10.1007/s00381-004-1032-1, 15455248.
26. Winter CD, Pringle AK, Clough GF, Church MK. Raised parenchymal interleukin-6 levels correlate with improved outcome after traumatic brain injury. Brain 2004, 127:315-320. 10.1093/brain/awh039, 14645145.
27. Chiaretti A, Antonelli A, Mastrangelo A, Pezzotti P, Tortorolo L, Tosi F, et al. Interleukin-6 and nerve growth factor upregulation correlates with improved outcome in children with severe traumatic brain injury. J Neurotrauma 2008, 25:225-234. 10.1089/neu.2007.0405, 18352836.
28. Arand M, Melzner H, Kinzl L, Bruckner UB, Gebhard F. Early inflammatory mediator response following isolated traumatic brain injury and other major trauma in humans. Langenbecks Arch Surg 2001, 386:241-248. 10.1007/s004230100204, 11466564.
29. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999, 106:506-512. 10.1016/S0002-9343(99)00066-2, 10335721.
30. Oto J, Suzue A, Inui D, Fukuta Y, Hosotsubo K, Torii M, et al. Plasma proinflammatory and anti-inflammatory cytokine and catecholamine concentrations as predictors of neurological outcome in acute stroke patients. J Anesth 2008, 22:207-212. 10.1007/s00540-008-0639-x, 18685925.
31. Stangl M, Zerkaulen T, Theodorakis J, Illner W, Schneeberger H, Land W, et al. Influence of brain death on cytokine release in organ donors and renal transplants. Transplant Proc 2001, 33:1284-1285. 10.1016/S0041-1345(00)02479-9, 11267293.
32. Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 2009, 28:2940-2947. 10.1038/onc.2009.180, 19581928.
33. Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 2001, 86:1154-1159. 10.1210/jc.86.3.1154, 11238501.
34. Wetmore JB, Lovett DH, Hung AM, Cook-Wiens G, Mahnken JD, Sen S, et al. Associations of interleukin-6, C-reactive protein and serum amyloid A with mortality in haemodialysis patients. Nephrology (Carlton) 2008, 13:593-600. 10.1111/j.1440-1797.2008.01021.x, 18826487.
35. Ali C, Nicole O, Docagne F, Lesne S, MacKenzie ET, Nouvelot A, et al. Ischemia-induced interleukin-6 as a potential endogenous neuroprotective cytokine against NMDA receptor-mediated excitotoxicity in the brain. J Cereb Blood Flow Metab 2000, 20:956-966. 10.1097/00004647-200006000-00008, 10894179.
36. Carlson NG, Wieggel WA, Chen J, Bacchi A, Rogers SW, Gahring LC. Inflammatory cytokines IL-1 alpha, IL-1 beta, IL-6, and TNF-alpha impart neuroprotection to an excitotoxin through distinct pathways. J Immunol 1999, 163:3963-3968.
37. Penkowa M, Giralt M, Carrasco J, Hadberg H, Hidalgo J. Impaired inflammatory response and increased oxidative stress and neurodegeneration after brain injury in interleukin-6-deficient mice. Glia 2000, 32:271-285. 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5, 11102968.
38. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993, 39:561-577.
39. Cavaillon JM. Cytokines and macrophages. Biomed Pharmacother 1994, 48:445-453. 10.1016/0753-3322(94)90005-1, 7858154.
40. Beagley KW, Elson CO. Cells and cytokines in mucosal immunity and inflammation. Gastroenterol Clin North Am 1992, 21:347-366.
41. Zhang Y, Lin JX, Vilcek J. Synthesis of interleukin 6 (interferon-beta 2/B cell stimulatory factor 2) in human fibroblasts is triggered by an increase in intracellular cyclic AMP. J Biol Chem 1988, 263:6177-6182.
42. Yoshizaki K, Nishimoto N, Matsumoto K, Tagoh H, Taga T, Deguchi Y, et al. Interleukin 6 and expression of its receptor on epidermal keratinocytes. Cytokine 1990, 2:381-387. 10.1016/1043-4666(90)90069-6, 2129417.
43. Loppnow H, Libby P. Comparative analysis of cytokine induction in human vascular endothelial and smooth muscle cells. Lymphokine Res 1989, 8:293-299.
44. Hensler T, Sauerland S, Bouillon B, Raum M, Rixen D, Helling HJ, et al. Association between injury pattern of patients with multiple injuries and circulating levels of soluble tumor necrosis factor receptors, interleukin-6 and interleukin-10, and polymorphonuclear neutrophil elastase. J Trauma 2002, 52:962-970. 10.1097/00005373-200205000-00023, 11988666.
45. Zemlan FP, Jauch EC, Mulchahey JJ, Gabbita SP, Rosenberg WS, Speciale SG, et al. C-tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinical outcome. Brain Res 2002, 947:131-139. 10.1016/S0006-8993(02)02920-7, 12144861.
46. Pelinka LE, Kroepfl A, Leixnering M, Buchinger W, Raabe A, Redl H. GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. J Neurotrauma 2004, 21:1553-1561. 10.1089/neu.2004.21.1553, 15684648.
47. Herrmann M, Jost S, Kutz S, Ebert AD, Kratz T, Wunderlich MT, et al. Temporal profile of release of neurobiochemical markers of brain damage after traumatic brain injury is associated with intracranial pathology as demonstrated in cranial computerized tomography. J Neurotrauma 2000, 17:113-122. 10.1089/neu.2000.17.113, 10709869.
48. Shore PM, Thomas NJ, Clark RS, Adelson PD, Wisniewski SR, Janesko KL, et al. Continuous versus intermittent cerebrospinal fluid drainage after severe traumatic brain injury in children: effect on biochemical markers. J Neurotrauma 2004, 21:1113-1122. 10.1089/neu.2004.21.1113, 15453982.
49. Dash PK, Zhao J, Hergenroeder GW, Moore AN. Biomarkers fof the diagnosis, prognosis, and evaluation of treatment efficacy for traumatic brain injury. Neurotherapeutics 7:100-114. 10.1016/j.nurt.2009.10.019, 20129502.
50. Dash PK, Redell JB, Hergenroeder GW, Zhao J, Clifton GL, Moore AN. Serum ceruloplasmin and copper are early biomarkers of elevated intracranial pressure. J Neurosci Res